Biotie has achieved a milestone in its collaboration with Wyeth for the development of PDE10 (phosphodiesterase 10) inhibitors for schizophrenia. Wyeth will trigger a $1.0m milestone payment to Biotie.
Biotie has demonstrated that inhibitors of PDE10 display positive antipsychotic activity in experimental models, indicating the potential for a superior efficacy and tolerability profile versus current standard therapies.
Timo Veromaa, president and CEO of Biotie said: We are pleased with the progress we have made in collaboration with Wyeth on the PDE10 inhibitor program and look forward to beginning our work together in the clinic. We believe this partnership provides further validation for our PDE platform technology, which has already provided us with one active clinical program and several pre-clinical programs.